Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care: Strong growth despite the pandemic, Annual General Meeting approves 23rd straight dividend increase

share with twitter share with LinkedIn share with facebook
08/27/2020 | 08:02am EDT

Press Release

Fresenius Medical Care, the world's largest provider of dialysis products and services, has proved resilient during the COVID-19 pandemic and remains on its growth course, Chief Executive Officer Rice Powell said at today's Annual General Meeting. In order to protect all participants' health amid the pandemic, this year's meeting, originally set for May, was not held as usual in Frankfurt but as a virtual meeting on the Internet. Powell spoke from the company's North America headquarters in Waltham, Massachusetts, in the United States, while other Management and Supervisory Board members joined from locations around the world.

In his speech to the shareholders, Powell stressed the essential contributions that Fresenius Medical Care is making during the pandemic: 'We have proven to our patients that we are there for them, no matter what. All of our production sites are fully operational and able to meet demand, our supply chains remain intact, and our clinics open. This is vital for our patients.'

The CEO confirmed the company's 2020 outlook, with revenue and net income growth in the mid to high single-digit range expected. 'Our strong performance in the first half of the year proves the resilience of our vertically integrated business model, and it shows our strength in taking care of people - even in a challenging environment,' said Powell. 'Summing up, we intend to continue our success story. Fresenius Medical Care is well-positioned to grow further - this year and in the post-COVID era.'

In addition, Powell outlined the company's Global Sustainability Program, which was started last year and is under his direct responsibility. Management Board members' compensation will in future also be oriented to this program. The new compensation system, which includes a non-financial performance target, was approved by the Annual General Meeting with a large majority.

A large shareholder majority of 99.89 percent also approved the company's 23rd consecutive dividend increase. The dividend will be raised by 3 percent, to €1.20 per share.

Shareholder majorities of 96.60 and 94.58 percent, respectively, approved the actions of the General Partner and the Supervisory Board in 2019.

At the virtual Annual General Meeting, 79 percent of the registered capital was represented.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,036 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 347,683 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


FMC - Fresenius Medical Care AG & Co. KGaA published this content on 27 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2020 12:02:15 UTC

share with twitter share with LinkedIn share with facebook
10/23FRESENIUS SE : Receives a Buy rating from Goldman Sachs
10/23FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Goldman Sachs
10/22FRESENIUS SE : Credit Suisse reiterates its Neutral rating
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse reaffirms its Neutral ratin..
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse remains Neutral
10/21FRESENIUS SE : Berenberg reiterates its Buy rating
10/21Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva t..
10/21FRESENIUS SE : Barclays reiterates its Buy rating
10/21FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Barclays
10/20FRESENIUS MEDICAL CARE : gets FDA approval for Biofine® PD solution bags
More news
Financials (USD)
Sales 2020 21 505 M - -
Net income 2020 1 543 M - -
Net Debt 2020 14 311 M - -
P/E ratio 2020 15,4x
Yield 2020 1,74%
Capitalization 23 836 M 23 792 M -
EV / Sales 2020 1,77x
EV / Sales 2021 1,66x
Nbr of Employees 124 736
Free-Float 65,1%
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,54 $
Last Close Price 81,40 $
Spread / Highest target 41,4%
Spread / Average Target 22,3%
Spread / Lowest Target -1,84%
EPS Revisions
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer